Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 8/22/2025

Medication Management in Hematuria

Introduction to Medication Management

  • Hematuria management involves careful consideration of medication use, including anticoagulants and antiplatelet agents, to minimize bleeding risk, as recommended by the American College of Cardiology 1, 2

Aspirin Therapy

  • Discontinue aspirin immediately in patients with hematuria, as it contributes to bleeding risk, and resume only after thorough evaluation and with cardiology consultation if used for cardiovascular protection, as recommended by the American Gastroenterological Association 3
  • Resume aspirin once hematuria resolves, with consideration of adding a proton pump inhibitor if aspirin must be continued, based on evidence from the Gut journal 3

Anticoagulant/Antiplatelet Therapy Resumption

  • Consult with specialists, such as cardiology or rheumatology, before resuming anticoagulant or antiplatelet therapy, considering the strength of evidence for individual patient cases 3
  • Anemia management in patients on anticoagulation involves a thorough evaluation for the cause of anemia, including assessing for GI bleeding, evaluating for hemolysis, checking for nutritional deficiencies, and considering bone marrow analysis if no obvious cause is found, as recommended by the American Society of Clinical Oncology 1

Anemia Management

  • Transfuse to achieve a hemoglobin level of 7-8 g/dL in patients on anticoagulation, and not to transfuse more than the minimum number of RBC units necessary to reach this target, as recommended by the American Society of Clinical Oncology 1
  • Monitor hemoglobin levels weekly until stable, as recommended by the American Society of Clinical Oncology 4
  • Consider folic acid 1 mg daily supplementation, according to the American Society of Clinical Oncology 1

Anticoagulant Therapy

  • Direct oral anticoagulants (DOACs) are recommended as first-line therapy for patients with hypercoagulable states, with rivaroxaban being the preferred option due to having the most clinical evidence in this setting, as recommended by the American College of Cardiology and American Heart Association 5, 6
  • Apixaban is an alternative DOAC with a good benefit/risk profile, with dosing based on standard VTE protocols, and is a good option for patients with mild-moderate renal impairment (27% renally cleared), as stated by the American College of Chest Physicians and American College of Cardiology 5, 7
  • Dabigatran dosing is 150 mg twice daily if CrCl >30 mL/min, and 75 mg twice daily if CrCl 15-30 mL/min, as recommended by the American College of Cardiology and European Society of Anaesthesiology 8, 9, 10
  • Edoxaban is administered as a synthetic pentasaccharide that inhibits Factor Xa, with dosing based on weight: 5 mg if <50 kg, 7.5 mg if 50-100 kg, and 10 mg if >100 kg, as recommended by the American College of Cardiology 5

Reversal Agents and Monitoring

  • Dabigatran has a specific reversal agent (idarucizumab) available for emergency situations, and warfarin has vitamin K/PCC available for reversal, as recommended by the American College of Cardiology 8
  • Andexanet alfa is the specific reversal agent for apixaban, though prothrombin complex concentrate can be used if andexanet alfa is unavailable, as recommended by the American College of Cardiology 8
  • Regular INR monitoring (target 2.0-3.0) is required for warfarin, and aPTT monitoring (target 1.5-3 times baseline) is required for argatroban, as recommended by the American College of Cardiology 5
  • Regular renal function monitoring is essential for patients on dabigatran, especially in elderly patients, as recommended by the European Society of Cardiology 9, 11
  • For high bleeding risk procedures, rivaroxaban, apixaban, and edoxaban should be interrupted 3 days before, as recommended by the European Society of Anaesthesiology 10
  • For procedures with low bleeding risk, the last dose of dabigatran should be 3 days before the procedure if CrCl is >30 mL/min, based on recommendations from the European Society of Anaesthesiology 10

Evaluation and Management of Hematuria

  • When evaluating a patient with hematuria on anticoagulants, assess severity of bleeding, including quantifying amount of blood in urine, determining duration of hematuria, checking for associated symptoms, and evaluating hemodynamic stability, and consider a full urologic evaluation, including urine cytology, renal imaging, and cystoscopy if gross hematuria or persistent microscopic hematuria, as recommended by the American College of Cardiology 2, 9
  • Laboratory evaluation should include complete blood count, serum creatinine, and urinalysis to confirm hematuria and check for infection, and calculate creatinine clearance using Cockcroft-Gault formula, as recommended by the American College of Cardiology 2
  • Temporarily discontinue anticoagulants like Eliquis if hematuria is significant, ensure adequate hydration, and monitor vital signs and urine output, and consider restarting Eliquis once hematuria resolves, with possible dose reduction based on patient factors, as recommended by the American College of Cardiology 2, 8

Drug Interactions and Concomitant Therapy

  • Drug interactions must be carefully evaluated, particularly with P-glycoprotein inhibitors and CYP3A4 inhibitors, as recommended by the American College of Chest Physicians 7
  • Avoid concomitant use of antiplatelet agents with anticoagulants, as it significantly increases bleeding risk, according to the American Heart Association, as cited in Circulation: Arrhythmia and Electrophysiology 12
  • Use the lowest effective dose of antiplatelet therapy if absolutely necessary, to minimize the risk of bleeding complications, as recommended by the American Heart Association 12

REFERENCES

12

drug interactions affecting oral anticoagulant use. [LINK]

Circulation: Arrhythmia and Electrophysiology, 2022